Profile data is unavailable for this security.
About the company
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
- Revenue in USD (TTM)0.00
- Net income in USD-153.16m
- Incorporated2016
- Employees85.00
- LocationCullinan Therapeutics IncOne Main Street, Suite 1350CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 410-4650
- Fax+1 (302) 655-5049
- Websitehttps://cullinantherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.03bn | 197.00 | 35.70 | 5.14 | 5.22 | 1.82 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 1.06bn | 150.00 | -- | 5.82 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.10bn | 536.00 | -- | -- | -- | 3.09 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Enliven Therapeutics Inc | 0.00 | -71.58m | 1.10bn | 46.00 | -- | 3.94 | -- | -- | -2.18 | -2.18 | 0.00 | 5.95 | 0.00 | -- | -- | 0.00 | -40.31 | -42.26 | -44.80 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.11bn | 267.00 | -- | -- | -- | 2.51 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.13bn | 586.00 | -- | 0.9953 | -- | 31.46 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.14bn | 85.00 | -- | 2.51 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.15bn | 173.00 | -- | 2.28 | -- | 12.84 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Pharvaris NV | 0.00 | -108.63m | 1.15bn | 82.00 | -- | 2.71 | -- | -- | -2.72 | -2.72 | 0.00 | 7.91 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.17bn | 278.00 | -- | 4.97 | -- | 5.21 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| MannKind Corp | 224.60m | 8.49m | 1.17bn | 414.00 | 184.38 | -- | 86.94 | 5.21 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Novavax Inc | 983.71m | -545.06m | 1.25bn | 1.54k | -- | -- | -- | 1.27 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.27bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to Cullinan Therapeutics Inc's reporting currency: US Dollar USD
38.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Franklin Advisers, Inc.as of 31 Dec 2023 | 3.26m | 7.57% |
| BVF Partners LPas of 31 Dec 2023 | 3.20m | 7.42% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.16m | 5.01% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.73m | 4.01% |
| Braidwell LPas of 31 Dec 2023 | 1.24m | 2.88% |
| Corebridge Institutional Investments (US) LLCas of 31 Dec 2023 | 1.22m | 2.84% |
| Citadel Advisors LLCas of 31 Dec 2023 | 1.02m | 2.37% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 993.38k | 2.31% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 859.06k | 2.00% |
| Tang Capital Management LLCas of 31 Dec 2023 | 771.14k | 1.79% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
